title: Antibody therapy of cancer.
abstract: The use of monoclonal antibodies (mAbs) for cancer therapy has achieved considerable success in recent years. Antibody-drug conjugates are powerful new treatment options for lymphomas and solid tumours, and immunomodulatory antibodies have also recently achieved remarkable clinical success. The development of therapeutic antibodies requires a deep understanding of cancer serology, protein-engineering techniques, mechanisms of action and resistance, and the interplay between the immune system and cancer cells. This Review outlines the fundamental strategies that are required to develop antibody therapies for cancer patients through iterative approaches to target and antibody selection, extending from preclinical studies to human trials.
authors.affiliation: Ludwig Institute for Cancer Research; University of Melbourne; and Centre for PET, Austin Hospital, Melbourne, Victoria 3084, Australia. andrew.scott@ludwig.edu.au
authors.forename: Andrew M
authors.initials: AM
authors.lastname: Scott
authors.forename: Jedd D
authors.initials: JD
authors.lastname: Wolchok
authors.forename: Lloyd J
authors.initials: LJ
authors.lastname: Old
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D000951:Antigens, Neoplasm / Q000276:immunology / Q000378:metabolism; D000970:Antineoplastic Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D017277:Drug Approval; D004337:Drug Carriers / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D006801:Humans; D056747:Immunomodulation; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D014018:Tissue Distribution; D019139:Tumor Escape
chemical_list: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D004337:Drug Carriers